After matching 168,428 patients in each group, GLP-1 receptor agonist users had a VTE rate of 11.0 per 1,000 patient-years compared to 12.9 per 1,000 patient-years in those taking DPP-4 inhibitors (a different class of diabetes medication)
It doesn't require a prescription and works through a different, much milder pathway
Earlier studies have found that combination therapy with an SGLT2 inhibitor and a GLP-1 RA, compared with monotherapy with either drug alone, is associated with improved control of cardiovascular risk factors, including a greater reduction of HbA 1c , BP and body weight, demonstrating additive effects [16,17,18]
What the emergency room does If you go to an ER for a semaglutide overdose, the treatment is supportive care